• Cutting-edge cancer immunotherapy based on T-cell receptor technologies

    Cutting-edge cancer immunotherapy based on T cell receptor technologies

  • Cancer treatment redefined - tailoring the immune system to fight cancer

    Zelluna Immunotherapy is a company dedicated to the development of innovative immunotherapies for the treatment of a broad range of cancers with a high unmet medical need. The company’s core asset consists of a large panel of tumour specific T cell receptors (TCRs) isolated from long-term survivors from cancer vaccine trials that can be used in multiple therapeutic settings.

    • For inquiries please contact:
      Zelluna Immunotherapy AS
      Ullernchausséen 64
      0379 Oslo
      Norway

      Email:This email address is being protected from spambots. You need JavaScript enabled to view it.